HAYA Therapeutics raised $65 million in Series A funding to advance clinical trials for HTX-001, a therapy targeting heart failure. The financing aims to strengthen its RNA-guided regulatory genome platform.
Amount Raised
$65 Million
Round Type
Series A
LausanneBiotechnologyHealth CareScience And EngineeringInvestors
Description
HAYA Therapeutics announced that it has raised $65 million in Series A funding. The company plans to use the funds for the clinical development of its lead candidate HTX-001 in heart failure. HAYA also aims to expand its RNA-guided regulatory genome pipeline. This funding reflects strong investor confidence in HAYA’s innovative approach.
Quick answer
Haya Therapeutics raised $65 Million in a Series A round, dated May 8, 2025. Investors: Earlybird Venture Capital and Sofinnova Partners. Haya Therapeutics is based in Lausanne, Vaud, Switzerland.
- How much did Haya Therapeutics raise?
- Haya Therapeutics raised $65 Million in a Series A round on May 8, 2025.
- Who invested in Haya Therapeutics?
- Earlybird Venture Capital and Sofinnova Partners are named as investors in this round.
- What does Haya Therapeutics do?
- HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states..
- Where is Haya Therapeutics based and how big is it?
- Haya Therapeutics is based in Lausanne, Vaud, Switzerland.
- Who are the decision-makers at Haya Therapeutics?
- Fundz holds 1 contact at Haya Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Haya Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- MAIA Biotechnology raised $695K (Seed) on May 28, 2025.
- Shuttle Pharmaceutical Holdings raised $4.3M (Seed) on June 20, 2025.
- PointCaré raised $1.7M (Seed) on June 19, 2025.
- Actio Biosciences raised $66M (Series B) on June 18, 2025.
- Lyrebird Health raised $8.9M (Funding Round) on June 18, 2025.
- DESKi raised $6M (Seed) on June 18, 2025.
Who to call at Haya Therapeutics, and when
A new round usually means Haya Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Haya Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Haya Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Haya Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Haya Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansHaya Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.